Ciprofibrate (Win35833) is a potentperoxisome proliferatorand increases the phosphorylation level of thePPARalpha^[1]. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias^[2].

Ciprofibrate (500 μM; 4 hours) increases the PPARa phosphorylation level in rat Fao cells^[1].
In a LucLite assay, Ciprofibrate (10-100μM; 24 hours) induces PPARR activation by existing increased LUC activities in the rat liver H4IIEC3 cells transfected with PPRE-AB LUC reporter gene plasmid^[2].
Ciprofibrate (10-100 μM; 24 hours) is not cytotoxic for HepG2 cells, and the cell viability is 99.7%^[3].
Ciprofibrate (100 μM; 24 hours) also abolishes FFAs mixture-induced lipid deposition and decreases FFAs mixture-increased TG contents in HepG2 cells^[3].
Ciprofibrate (100 μM; 24 hours) almost entirely eliminates the FFAs mixture-induced inflammatory cytokines overproduction, including MCP-1, TNF-α, and IL-6 in HepG2 cells^[3].

Ciprofibrate (oral administration; 10 mg/kg/day; 3 days) does not result in any significant effects on body weight or absolute liver weight for MCD diet-fed mice. Ciprofibrate improves hepatic steatosis and reduced hepatic necro-inflammation in MCD diet-fed mice. It also reduced hepatic cytokine protein and mRNA levels (MCP-1, TNFα and IL-6) as compared to those of choline-deficient (MCD) diet-fed mice^[3].

289.15

Solid

C₁₃H₁₄Cl₂O₃

52214-84-3

环丙贝特；氯环丙妥明

Room temperature in continental US; may vary elsewhere.

DMSO : ≥ 100 mg/mL(345.84 mM)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (8.65 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (8.65 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.5 mg/mL (8.65 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (8.65 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。